MESO
HealthcareMesoblast Limited · Biotechnology · $2B
What is Mesoblast Limited?
Mesoblast Limited is an Australian biopharmaceutical company focused on developing allogeneic cellular medicines — therapies derived from donor cells that can be administered without patient-specific customization. Its pipeline spans several serious and hard-to-treat conditions across multiple therapeutic areas.
Mesoblast builds its pipeline on a proprietary regenerative medicine platform centered on mesenchymal lineage cells — a specialized cell type with broad immunomodulatory and tissue-repair properties. The company advances candidates through late-stage clinical trials targeting conditions such as graft versus host disease, chronic heart failure, and degenerative disc disease. Revenue and commercial traction depend heavily on trial outcomes and regulatory approvals, making this a development-stage model with high binary risk at each program milestone.
Mesoblast was incorporated in 2004 and is headquartered in Melbourne, Australia.
- Remestemcel-L — cell therapy for steroid-refractory acute graft versus host disease
- Rexlemestrocel-L — investigational treatment for advanced chronic heart failure
- MPC-06-ID — cell therapy candidate for chronic low back pain
- MPC-300-IV — pipeline asset targeting biologic-refractory rheumatoid arthritis
- Strategic partnerships with Tasly, JCR Pharmaceuticals, and Grünenthal for regional commercialization
Is MESO a Good Stock to Buy?
UQS Score rates MESO as Below Average overall, reflecting a profile where one standout pillar sits alongside meaningful structural weaknesses.
The Growth pillar registers as Strong — notable for a clinical-stage biotech — suggesting the pipeline carries meaningful upside potential if key programs advance. The Risk pillar reads as Good, indicating the company's financial risk profile is relatively managed compared to many peers at a similar development stage.
Both the Quality and Moat pillars score Weak, reflecting the absence of durable commercial revenues and a competitive position that remains unproven. Valuation is flagged as Elevated, meaning the market is already pricing in considerable optimism.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MESO pay dividends?
No — Mesoblast Limited does not currently pay a dividend.
Mesoblast does not pay a dividend. As a clinical-stage biopharmaceutical company, capital is directed toward funding trials, regulatory submissions, and partnership development rather than shareholder distributions. Investors in MESO are typically seeking pipeline-driven capital appreciation rather than income, and a dividend is unlikely until the company reaches sustained commercial profitability.
When does MESO report earnings?
Mesoblast reports financial results on a quarterly cadence, consistent with its US-listed equity obligations.
As a development-stage company, quarterly results are shaped more by cash burn, milestone payments, and partnership revenues than by traditional operating income. Progress on clinical programs and regulatory interactions tend to move the stock more than headline earnings figures.
For the most recent quarter's results and management commentary, visit Mesoblast's investor relations page directly.
MESO Price History
+4.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Mesoblast Limited?
Based on Mesoblast Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MESO Long-term Outlook
Mesoblast's fundamental outlook is driven almost entirely by clinical and regulatory catalysts. The Strong Growth pillar signals that the pipeline carries meaningful potential, particularly if late-stage programs in graft versus host disease and heart failure reach approval. However, the Weak Quality and Moat pillars serve as a reminder that commercial execution remains unproven, and the Elevated Valuation suggests the current price already reflects a degree of success that has not yet materialized.
Growth drivers
- Late-stage clinical programs approaching potential regulatory decision points
- Existing regional partnerships providing non-dilutive milestone and royalty revenue pathways
- Expanding therapeutic applications of the mesenchymal lineage cell platform
Key risks
- Clinical trial failure or regulatory rejection could sharply reset expectations
- Elevated valuation leaves limited margin of safety if timelines slip
- Ongoing cash consumption typical of development-stage biotechs creates dilution risk
MESO vs Peers
Mesoblast operates in a competitive specialty biotech landscape alongside other clinical-stage and commercial-stage companies targeting immune-mediated and inflammatory conditions.
Aurinia has an approved commercial product in lupus nephritis, giving it a revenue base that Mesoblast's pipeline has not yet achieved.
Syndax focuses on oncology and hematology with a small-molecule approach, contrasting with Mesoblast's cell-therapy platform.
Ocular Therapeutix targets ophthalmic conditions using sustained-release drug delivery, a narrower therapeutic focus than Mesoblast's multi-indication cell therapy strategy.
Frequently Asked Questions
What does Mesoblast do?
Mesoblast develops allogeneic cellular medicines — off-the-shelf therapies built on mesenchymal lineage cells. Its pipeline targets serious conditions including graft versus host disease, chronic heart failure, degenerative disc disease, and inflammatory diseases. The company operates across the US, Australia, and several other markets, with commercial partnerships in China and Europe.
Does MESO pay dividends?
No, Mesoblast does not currently pay a dividend. The company is in a clinical development phase and directs available capital toward advancing its pipeline and funding operations. Income-focused investors should be aware that distributions are not part of the current capital allocation strategy.
When does MESO report earnings?
Mesoblast reports on a quarterly cadence as a US-listed company. Because it is development-stage, pipeline updates and cash runway disclosures often carry more market weight than traditional earnings metrics. Check Mesoblast's investor relations page for the current reporting schedule.
Is MESO a good stock to buy?
The UQS Score rates MESO as Below Average overall. The Growth pillar is Strong and Risk is Good, but Quality and Moat are both Weak, and Valuation is Elevated. That combination means the stock carries meaningful upside potential alongside real structural risks. The complete pillar breakdown is available to UQS Pro members.
Is MESO overvalued?
The UQS Valuation pillar for MESO is rated Elevated, suggesting the current market price already reflects a degree of pipeline success that has not yet been commercially demonstrated. For clinical-stage biotechs, elevated valuations are common when late-stage catalysts are anticipated, but they also reduce the margin of safety if timelines shift.
How does MESO compare to its competitors?
Compared to peers like Aurinia Pharmaceuticals, Syndax Pharmaceuticals, and Ocular Therapeutix, Mesoblast is distinguished by its cell-therapy platform and multi-indication pipeline. Unlike Aurinia, which has a commercial product, Mesoblast remains pre-revenue at scale. Its approach is more platform-oriented than the narrower therapeutic focus of Syndax or Ocular Therapeutix.
What is MESO's market cap bracket?
Mesoblast is classified as a mid-cap company. Within the biotech space, mid-cap status for a development-stage company typically reflects meaningful pipeline value being priced in ahead of commercial revenues.
Who founded Mesoblast?
Mesoblast was founded by Professor Silviu Itescu, who has served as the company's chief executive. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. Further founding context is available through Mesoblast's corporate history disclosures.
Is MESO a long-term quality investment?
From a long-term quality standpoint, the UQS framework flags Weak scores on both Quality and Moat pillars for MESO, indicating that durable competitive advantages and consistent financial performance have not yet been established. The Strong Growth pillar suggests long-term potential exists, but it is contingent on clinical and regulatory execution over time.
What is the main competitive advantage of Mesoblast?
Mesoblast's primary differentiation is its proprietary mesenchymal lineage cell platform, which underpins multiple pipeline programs across different disease areas. Allogeneic cell therapies — designed to work across patients without individual customization — represent a manufacturing and scalability advantage over autologous approaches, though commercial proof of this advantage remains pending.
What sector does MESO belong to?
Mesoblast operates in the Healthcare sector, specifically within biopharmaceuticals and regenerative medicine. Its focus on cell-based therapies places it in an emerging sub-segment of the broader biotech industry, where clinical outcomes and regulatory timelines drive most of the investment thesis.
Is MESO a growth stock or value stock?
Based on the UQS pillar profile, MESO leans toward a growth classification — the Growth pillar is rated Strong. However, the Elevated Valuation pillar means investors are already paying a premium for that growth potential. It is not a value stock in the traditional sense, given the absence of established earnings or cash flows.
Unlock Full MESO Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics and trend data
- ✓Compare MESO against sector peers on every pillar
- ✓See the complete Quality and Moat breakdown
- ✓Track valuation changes over time with Pro tools
- ✓Get the full analyst-grade view in one dashboard
Pro Analysis
MESO — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 38.9 | 0.8 | 39.0 | 81.5 | 69.0 | 15.0 | +0.3 |
| May 17, 2026 | 38.6 | 0.8 | 39.0 | 81.5 | 69.0 | 13.6 | -0.2 |
| May 14, 2026 | 38.8 | 0.8 | 39.0 | 81.5 | 69.0 | 14.4 | -0.1 |
| May 12, 2026 | 38.9 | 0.8 | 39.0 | 81.5 | 69.0 | 15.0 | +5.2 |
| May 10, 2026 | 33.7 | 0.0 | 39.0 | 81.5 | 36.9 | 14.3 | 0.0 |
| May 8, 2026 | 33.7 | 0.0 | 39.0 | 81.5 | 36.9 | 14.2 | -4.6 |
| May 7, 2026 | 38.3 | 0.8 | 39.0 | 81.5 | 69.0 | 11.1 | 0.0 |
| May 5, 2026 | 38.3 | 0.8 | 39.0 | 81.5 | 69.0 | 11.3 | -2.9 |
| May 3, 2026 | 41.2 | 0.8 | 39.0 | 81.5 | 69.0 | 30.7 | -0.1 |
| Apr 26, 2026 | 41.3 | 0.8 | 39.0 | 81.5 | 69.0 | 31.1 | +0.3 |
MESO — Pillar Breakdown
Quality
— 0.8/100 (25%)Mesoblast Limited currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 81.5/100 (20%)Mesoblast Limited is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 69.0/100 (15%)Mesoblast Limited maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 12.9/100 (15%)Mesoblast Limited appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 39/100 (25%)Mesoblast Limited possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MESO.
Score Composition
Financial Data
More Stock Analysis
How is the MESO UQS Score Calculated?
The UQS (Unified Quality Score) for Mesoblast Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Mesoblast Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Mesoblast Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.